Three First-tier Instrument Sets of Suzhou
Health First Received SFDA Approval

Nov 9, 2012, Suzhou—Three MIS instrument sets including the spine MIS instrument set, the LISS aiming system for proximal tibia and the LISS aiming system for distal femur developed by Suzhou Health Medical Appliance Co., Ltd, a wholly owned subsidiary of MicroPort Orthopedics, have obtained the registration certificate approved by Suzhou Food and Drug Administration. The term of validity for the registration certificate is four years.

The spine MIS instrument set is made up of 23 components. The product is designed for installing percutaneous screws and rods when taking percutaneous minimally invasive spinal operation. The LISS aiming system for proximal tibia and the LISS aiming system for distal femur contains 23 components respectively. The two LISS systems facilitated by the radiolucent PEEK handle are indicated for the stabilisation of fractures of the proximal tibia and distal femoral.

The technology of Minimally Invasive Surgery has the advantage of small incision, high precision, less bleeding volume in surgery, lower infection rate, etc. It has becoming the selling point of main orthopedics manufacturers. The deputy general manager of Shanghai MicroPort Orthopedics Co., Ltd., Lin Zhong said that the three first-tier instrument sets developed by Suzhou Health are all for minimally invasive traumatic and spinal operations and they represented a big step forward of MicroPort Orthopedics in the field of minimally invasive technique.

MicroPort Hercules™-T Systems
Re-registered Successfully in Thailand

MicroPort Hercules™-T Thoracic Stent-Graft System was re-registered successfully in Thailand. The registration is valid through March 15, 2014.

Hercules™-T Stent-Graft System is intended to treat fusiform or saccular aneurysms/penetrating ulcers in thoracic aorta.

Currently, Hercules™-T is also available in markets like China, Thailand, Venezuela, Philippines, Argentina, Brazil, and Uruguay. The products’ safety and efficacy features combined with various individually tailored sizes have really gained market’s recognition and gradually accepted by the local medical community.

Humble Stent, Prosperous future

More and more multinational corporations are attracted by rapid developing medical device market in China. Recently, Medtronic, Inc., a global leading medical device manufacturer, completed its acquisition of China Kanghui Holdings (NYSE: KH), an orthopedic devices Company in Changzhou, Jiangsu Province. The total consideration of acquisition exceeded US$800 million. The acquisition caught public attention extensively. It is known that domestic medical device companies in China compete with those MNCs by continuous innovation and gain advantage in the field of high end medical device such as the cardiovascular stent.

Yubo Fan, Chairman of SBME (Chinese Society Biomedical Engineering), introduced that the market scale of China medical device values approximately RMB 400 billion and is escalating by 20% every year, while 80% high-end medical device market share is occupied by foreign companies. However, domestic high end medical device manufacturers, MicroPort Scientific Corporation as a representative, have an excellent performance in the field of the cardiovascular stent over the past 10 years, have realized tremendous transformation from toddler to leap lap, and have occupied about 70% domestic market firmly.

Stent is a mesh tube inserted into a natural passage/conduit in the body to prevent aortic vessel block or stenosis. In China, more than 3.5 million people died from cardiovascular disease every year and the number is still uprising. For the past a few years, in this great demand and high profit market, local medical device manufacturers had lagged far behind of MNCs like Abbott, Johnson & Johnson and Medtronic. Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort Scientific Corporation, introduced that “comparing to foreign products, the PTCA balloon catheter technology had fallen behind MNCs’ for 20 years, and BMS technology (bare metal stent) for 4 or 5 years, while the DES (drug eluting stent) technology is now keeping pace with.”

Despite the decreased vascular restenosis rate with the improvement of technology, the application of DES raises the risk of a later period thrombosis. The patient has to take medicine for a long time after operation to prevent the fatal risk of thrombosis, though its probability is only 0.3%-0.5%.

Domestic medical device companies are striving to deal with this problem. Lepu Medical Technology (Beijing) Co., Ltd., a medical device manufacturer once ranked first of A-share GEM (growth enterprise market), launched Polymer-free Sirolimus-eluting Coronary Stent System in 2011. Weina Jiang, a securities researcher of Orient Securities Company Limited, commented that “Despite the slowing down growth traditional stents, the market of polymer-free stent has made a breakthrough with a trend of continuous development.”

Meanwhile, MicroPort Scientific Corporation (HK 00853), a Company listed in HKEx dominating domestic market share, introduced its third generation DES which was positively recommended by Dr.
Martin B Leon, the Chairman of TCT (Transcatheter Cardiovascular Therapeutics, the world’s largest educational meeting specializing in interventional cardiovascular medicine) in TCT 2012 this October.

Firehawk® Rapamycin Target Eluting Coronary Stent is the third generation drug-eluting stent system designed and manufactured exclusively by MicroPort Medical. It effectively decreases the probability of thrombosis by target release the drug directly to vessel, and significantly reduces the period of taking medicine after operation for patients.

The third generation drug-eluting stent system makes innovation in both concept and craftwork. Zhirong Tang, the Vice President of Coronary Products of MicroPort commented that: “It is difficult to make a trough on a stent as delicate as hair and it is even more difficult to fill the trough with drug and bring it into mass production.”

It is more encouraging that during the randomized controlled multicenter trial for Firehawk®, the third generation drug-eluting stent, Xience V the worldwide-recognized DES was chosen for head to head comparison. The results of the trial were very promising. Some of the major indicators of the third generation drug-eluting stent system showed equivalent efficacy as compared to Xience V and it even surpassed the Xience V in some areas.

An insider of medical device field said: “Innovation is the life of medical device industry. For a long time, Domestic medical device manufacturers had been at disadvantage place for lack of investment in Research &Development and lack of courage to compete with those MNCs. The breakthrough in DES segment will encourage domestic medical device manufacturers to compete with MNCs in other segment field such as orthopedic and CRM.”

Happiness Begins From Heart - MicroPort Heart Journey patient education serial lectures

Coronary heart disease is the global disease which severely impairs human health, meanwhile it’s also the principal disease that does harms to the health of the elderly and affects their life quality. The data shows that, many coronary heart disease patients are not died of the disease itself, but the ignorance of their own health and the unhealthy lifestyle. It is really a pity that treatment is delayed and then sudden coronary heart disease even sudden death is caused because of patient’s lack of the related knowledge about the disease. Therefore, the long-term and systematic education of the basic knowledge and treatment of coronary heart disease can help the patients to improve health protection skill.

MicroPort, where the patient always comes first, devotes itself to offering doctor and patient cost-effective medical treatments all the time, and makes great efforts to improve the life quality of the patients and make more contribution to public welfare.

In recent years, the Customer Service Department of MicroPort, which is a part of the programs for public good, insists carrying out public lectures of educating coronary heart disease patients, aiming at building up a platform for the communication of the patients, calling more people join the job that cares coronary heart disease patients and improves their life quality.

Under the joint efforts of both departments of Customer Service and Sales, the patient education serial lectures of MicroPort Heart Journey started in 2008. The number of hospitals participated is increasing every year. In the second half year of 2012, we have carried out approximately 20 series of activities in 37 hospitals including Sichuan Provincial People’s Hospital, The Sixth Hospital of Shanghai, Tianjin Baodi Hospital, The First People’s Hospital of Mengzi Yunnan, The People’s Hospital of Gejiu Yunnan, The 404 Hospital of Mianyang Sichuan and so on. The number of people attending the activities was about 1,000 totally, which had good influence on doctors and patients.

During the lecture, the specialists were good at teaching and explained profound theories in simple language, fully using pictures, animation, material objects and so on. They explained vividly to the patients the coronary heart disease and health knowledge, percutaneous coronary intervention principle, operation method, preoperative and postoperative attentions and so on, letting patients understand the therapeutic schedules clearly. Then they are more willing to co-operate the treatment, finally the therapeutic effect can be guaranteed. The feedback of patients showed that the contents of lectures were very practical. Specialists answered their questions in detail and increased patients’ confidence of taking surgical intervention treatment effectively. A patient of Guizhou Jinyang Hospital couldn’t help to tell us his story with emotions after he saw the stent by himself in the activity. He once suffered acute myocardial infarction and was in great danger. But he was fortunate to survive after an emergency coronary intervention operation He sighed: “What a miraculous stent! It’s a really high technology and I know how to prevent the disease and keep fit in the next after attending the lecture today.”

With the improvement of people’s health recognition and the popularity of coronary heart disease intervention treatment technology, serial health technology lectures will get more and more popular. In order to help more patients to understand...
The doctors are divided into two control groups; one group to use ultrasonic guidance (2D) and the other group to use enhancing ultrasonic guidance (3D) to repair bicuspid valve on pig by NeoChord DS1000. At the same time, they take notes on whether the operation time and the instrument path affect the aortic valves. The results show that the simplification and safety of operations with enhancing ultrasonic guidance improved apparently. At present, the technology is only used in animal experiment and is under progress of CE authentication. It is believed that the technology will be used in human in the near future.

Dr. Terry Peters is teaching in Medical Imaging and Medical Biophysics institute, Western University of Canada right now. He is also one of graduate student program of neurology and biomedical engineering.

MicroPort was awarded “Top 10 Enterprise Prize” by Shanghai Biological Pharmaceutical Industry Association

November 21, 2012—the 10th Anniversary Ceremony of Shanghai Biological Pharmaceutical Industry Association was held in Shanghai. An activity called “The Voting of Excellent Enterprises of the 10th Anniversary of Shanghai Biological Pharmaceutical Industry Association” was launched by the Association to commend and express gratitude to excellent member enterprises for their support and to encourage the enterprises to strive to be excellent. After 2 months of the voting and evaluation process of the Association, MicroPort was awarded “the Top 10 Enterprise Prize”.

Shanghai Biological Pharmaceutical Industry Association was founded in 2002 and it is also one of the first named “National Advanced NGOs” of Ministry of Civil Affairs. The number of its membership enterprises has increased from 87 to 212 which cover the whole industrial chain from Research & Development, production and to circulation in the field of modern biotechnology and medicine. The industry scale of the membership enterprises increased from RMB 8 billion at the beginning of the establishment in 2003 to more than RMB 140 billion in 2011. The association commits itself to promoting the development of biological pharmaceutical industry in Shanghai and enhancing its international competitiveness.